<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23789" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Isosorbide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Balasubramanian</surname>
            <given-names>Suryakumar</given-names>
          </name>
          <aff>Velammal Medical College and Research Institute</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chowdhury</surname>
            <given-names>Yuvraj S.</given-names>
          </name>
          <aff>State University of New York - Downstate</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Suryakumar Balasubramanian declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yuvraj Chowdhury declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>16</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23789.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Isosorbide is a medication used to treat and prevent angina pectoris in patients with coronary heart disease. It is in the nitrate class of drugs. This activity describes the indications, action, and contraindications for isosorbide as a valuable agent in treating angina pectoris due to coronary artery disease, heart failure with reduced ejection fraction, and achalasia. This activity will highlight the mechanism of action, adverse event profile, off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions pertinent to the health care team members in managing patients with angina pectoris due to coronary artery disease and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of isosorbide.</p></list-item><list-item><p>Describe the potential adverse effects patients may experience when using isosorbide.</p></list-item><list-item><p>Review the appropriate monitoring necessary with isosorbide.</p></list-item><list-item><p>Summarize the importance of collaboration and communication amongst the interprofessional team to enhance care delivery and improve outcomes for patients with angina pectoris receiving isosorbide.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23789&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23789">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23789.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Porje initiated the research on isosorbide in Stockholm, and the drug was marketed in Sweden in 1946. Isosorbide dinitrate was synthesized in the United States in the 1950s by Harris and colleagues. After introducing isosorbide, its popularity temporarily decreased as Needleman and his colleagues questioned its efficacy as it underwent extensive biotransformation in the liver.<xref ref-type="bibr" rid="article-23789.r1">[1]</xref> This opinion changed after a few years, and now it gained worldwide acceptance. Isosorbide belongs to the nitrate group of medications that acts by releasing nitric oxide (N0), thereby causing vasodilation. Isosorbide is available in two forms: isosorbide mononitrate and isosorbide dinitrate.</p>
        <p>&#x000a0;<bold>FDA Approved Indications for Isosorbide Dinitrate&#x000a0;&#x000a0;</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Prevention or treatment of angina pectoris resulting from coronary artery disease - however, it is not recommended for use once the anginal episode has started because the onset of action is not sufficiently rapid enough to abort an acute anginal event. In the latter case, glyceryl trinitrate is preferable.</p>
          </list-item>
          <list-item>
            <p>Treatment of congestive heart failure. A fixed-dose combination of isosorbide dinitrate and hydralazine is approved to treat congestive heart failure in African Americans.<xref ref-type="bibr" rid="article-23789.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Non-FDA Approved Indications for Isosorbide Dinitrate</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Achalasia<xref ref-type="bibr" rid="article-23789.r3">[3]</xref><xref ref-type="bibr" rid="article-23789.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Diffuse esophageal spasms<xref ref-type="bibr" rid="article-23789.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>FDA Approved Indications for Isosorbide Mononitrate</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment of chronic angina pectoris due to coronary artery disease</p>
          </list-item>
          <list-item>
            <p>Along with non-selective beta-blockers (NSBB), it can be used as secondary prophylaxis in preventing recurrent variceal hemorrhage.<xref ref-type="bibr" rid="article-23789.r6">[6]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23789.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Isosorbide is a nitrate that exerts its pharmacologic effect by releasing nitric oxide (NO), an endothelium-derived relaxing factor (EDRF).NO is endogenously produced in the endothelium to dilate the blood vessels. Isosorbide undergoes bioactivation in the endoplasmic reticulum through the cytochrome P450 enzymes to release NO<xref ref-type="bibr" rid="article-23789.r7">[7]</xref>, which activates the enzyme soluble guanylyl cyclase in the vascular smooth muscles, thereby increasing the levels of intracellular cGMP and the associated protein kinases such as cGMP- dependent protein kinases(cGK-I). The cGMP activates the myosin light chain phosphatase (MLCP), causing dephosphorylation of the myosin light chain. cGMP-cGK-I inhibits the&#x000a0;inositol-1,4,5-trisphosphate (IP3)-dependent calcium release, decreasing the intracellular calcium.<xref ref-type="bibr" rid="article-23789.r8">[8]</xref><xref ref-type="bibr" rid="article-23789.r9">[9]</xref>&#x000a0;</p>
        <p>The decreased intracellular calcium inhibits the myosin light chain kinase(MLCK).<xref ref-type="bibr" rid="article-23789.r10">[10]</xref>&#x000a0;The MLCK, along with the unphosphorylated myosin light chain, causes the myosin head to detach from the actin component of the smooth muscle, resulting in smooth muscle relaxation and causing vasodilation. Isosorbide dilates the venous capacitance vessels, arterioles, and coronary arteries. But Its maximal effect is seen in venous capacitance vessels.<xref ref-type="bibr" rid="article-23789.r7">[7]</xref></p>
        <p>
<bold>Hemodynamics</bold>
</p>
        <p>Isosorbide helps alleviate the symptoms of angina by&#x000a0;increasing the myocardial blood flow and decreasing the myocardial oxygen demand. At therapeutic levels, it predominately dilates the venous capacitance vessels but also the coronary arteries and the arterioles. The predominant venodilation results in decreased venous return to the heart by reducing the left ventricular end-diastolic volume, left ventricular end-diastolic pressure(preload), and the ventricular wall tension,&#x000a0;thereby&#x000a0;indirectly facilitating subendocardial blood flow.<xref ref-type="bibr" rid="article-23789.r11">[11]</xref>&#x000a0;It directly increases the myocardial blood flow by dilating the large and medium-sized coronary arteries at higher doses.<xref ref-type="bibr" rid="article-23789.r11">[11]</xref> It decreases systemic vascular resistance (afterload) by dilating the peripheral arterioles. Because of this decrease in the heart's workload, myocardial oxygen demand becomes reduced. Long-term isosorbide therapy with appropriate drug-free intervals can improve the patient's exercise capacity and exercise hemodynamics in patients with chronic congestive heart failure.<xref ref-type="bibr" rid="article-23789.r12">[12]</xref></p>
      </sec>
      <sec id="article-23789.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The two forms of isosorbide (isosorbide mononitrate and isosorbide dinitrate) vary extensively in their pharmacokinetic properties. The liver contains organic nitrate reductase, which removes the nitrate group in a stepwise manner and ultimately inactivates the drug. After oral administration, isosorbide dinitrate undergoes an extensive first-pass effect in the liver, reducing the oral bioavailability to 20 percent.<xref ref-type="bibr" rid="article-23789.r13">[13]</xref> Hence the sublingual route, which avoids the first-pass effect, is preferred to achieve the therapeutic levels rapidly.<xref ref-type="bibr" rid="article-23789.r14">[14]</xref> In contrast, isosorbide mononitrate, an active metabolite of isosorbide dinitrate,&#x000a0;does not undergo the first-pass effect, and its bioavailability is 100 percent after oral administration.<xref ref-type="bibr" rid="article-23789.r15">[15]</xref><xref ref-type="bibr" rid="article-23789.r16">[16]</xref>&#x000a0;</p>
        <p>The elimination half-life of isosorbide dinitrate is 1 hour, while the elimination half-life of isosorbide mononitrate is 5 to 6 hours.<xref ref-type="bibr" rid="article-23789.r15">[15]</xref>&#x000a0;When a longer duration of action is needed, clinicians can use a slow-release oral preparation that contains an amount of drug to withstand the hepatic metabolism and maintain the required therapeutic level. Isosorbide is excreted primarily through the kidney as glucuronide derivatives of the de-nitrated metabolite.<xref ref-type="bibr" rid="article-23789.r17">[17]</xref> Isosorbide does not need dose adjustment in patients with renal and hepatic dysfunction.</p>
        <p>The commonly available forms of isosorbide are:</p>
        <p>
<bold>Short-acting</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Isosorbide dinitrate, sublingual - 2.5 to 10 mg (duration of action - 10 to 60 minutes)<xref ref-type="bibr" rid="article-23789.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Long-acting</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Isosorbide dinitrate, oral - 10 to 40 mg 3 times a day (duration of action - 4 to 6 hours)</p>
          </list-item>
          <list-item>
            <p>Isosorbide dinitrate, spray - 1.25 mg per dose</p>
          </list-item>
          <list-item>
            <p>Isosorbide dinitrate, oral sustained-release capsules/tablets - 40 mg,14 hours apart (duration of action:12 to 14 hours)</p>
          </list-item>
          <list-item>
            <p>Isosorbide mononitrate, oral - 20 mg twice daily, 7 hours apart (duration of action - 6 to 10 hours)</p>
          </list-item>
          <list-item>
            <p>Isosorbide mononitrate, oral sustained-release tablets - 30 to 120 mg daily</p>
          </list-item>
          <list-item>
            <p>A fixed-dose combination of isosorbide dinitrate (20 mg) and hydralazine hydrochloride (37.5 mg) has received approval for use in treating heart failure in African-Americans<xref ref-type="bibr" rid="article-23789.r19">[19]</xref><xref ref-type="bibr" rid="article-23789.r20">[20]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23789.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The adverse effects of isosorbide are due to the vasodilation of the venous capacitance vessels and the arterioles. The venodilation results in peripheral pooling of blood and arteriolar dilation, lowering systemic vascular resistance (afterload) and lowering blood pressure. Other adverse effects can be due to the reflex activity of the sympathetic nervous system due to vasodilation.</p>
        <p>The adverse effects of isosorbide are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache (greater than 10 percent)<xref ref-type="bibr" rid="article-23789.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>Reflex tachycardia (0.1 to 10 percent)</p>
          </list-item>
          <list-item>
            <p>Orthostatic hypotension (0.1 to 10 percent)</p>
          </list-item>
          <list-item>
            <p>Hypotension (0.1 to 10 percent)</p>
          </list-item>
          <list-item>
            <p>Cutaneous flushing (0.1 to 10 percent)</p>
          </list-item>
          <list-item>
            <p>Nausea, vomiting (0.1 to 10 percent)</p>
          </list-item>
          <list-item>
            <p>Dizziness (0.1 to 10 percent)</p>
          </list-item>
          <list-item>
            <p>Lightheadedness (0.1 to 10 percent)</p>
          </list-item>
          <list-item>
            <p>syncope (0.1 to 10 percent)<xref ref-type="bibr" rid="article-23789.r11">[11]</xref><xref ref-type="bibr" rid="article-23789.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Monday disease</italic> -&#x000a0; Monday disease is due to the development of tolerance throughout therapy. It presents with tachycardia, dizziness, and headache during re-exposure after a drug-free interval.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Methemoglobinemia</italic>(rare)<xref ref-type="bibr" rid="article-23789.r23">[23]</xref> - Nitrate ions released during the metabolism of isosorbide oxidize the hemoglobin into methemoglobin. However, routinely used dosage of isosorbide usually causes clinically insignificant elevation of methemoglobin, but it may be important in patients with coronary ischemia and anemia.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23789.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Several contraindications exist for the use of isosorbide.<xref ref-type="bibr" rid="article-23789.r18">[18]</xref> They are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Allergic to nitrates</p>
          </list-item>
          <list-item>
            <p>Concomitant use of isosorbide with PDE inhibitors such as sildenafil and tadalafil</p>
          </list-item>
          <list-item>
            <p>Concomitant use of isosorbide with riociguat, a soluble guanylate cyclase stimulator used for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension<xref ref-type="bibr" rid="article-23789.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>Right ventricular infarction</p>
          </list-item>
          <list-item>
            <p>Hypertrophic cardiomyopathy</p>
          </list-item>
        </list>
        <p>PDE inhibitors such as tadalafil and sildenafil work by inhibiting the phosphodiesterase (PDE) enzyme, which is involved in breaking down the cGMP. Concomitant use of isosorbide with PDE inhibitors will cause increased cGMP, resulting in life-threatening hypotension.<xref ref-type="bibr" rid="article-23789.r22">[22]</xref></p>
        <p>Isosorbide releases NO, which stimulates the soluble guanylate cyclase. Therefore, the concomitant use of isosorbide with riociguat (a soluble guanylate cyclase stimulator) will cause an increased level of cGMP resulting in&#x000a0;life-threatening hypotension.<xref ref-type="bibr" rid="article-23789.r24">[24]</xref>&#x000a0;</p>
        <p>Patients with right ventricular infarction are preload sensitive. Isosorbide decreases the preload and worsens the right ventricular output causing severe hypotension.</p>
        <p>In patients with hypertrophic cardiomyopathy, isosorbide decreases the preload and, hence, the left ventricular volume, worsening&#x000a0;left ventricular outflow tract obstruction.<xref ref-type="bibr" rid="article-23789.r11">[11]</xref></p>
        <p>Isosorbide use requires caution in the following conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Elderly patients with autonomic dysfunction due to a high risk of orthostatic hypotension</p>
          </list-item>
          <list-item>
            <p>Patients on diuretics will be volume depleted and can develop severe hypotension</p>
          </list-item>
          <list-item>
            <p>Patients who are taking other vasodilators due to the risk of severe hypotension</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23789.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Generally, isosorbide does not need any monitoring. However, monitoring is recommended in:</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients who have low blood pressure and low heart rate</p>
          </list-item>
          <list-item>
            <p>Patients who are on chronic diuretic therapy</p>
          </list-item>
          <list-item>
            <p>Elderly patients with underlying autonomic dysfunction</p>
          </list-item>
          <list-item>
            <p>Patients with right ventricular infarction who are preload sensitive</p>
          </list-item>
          <list-item>
            <p>Volume-depleted patients, e.g.,&#x000a0;from chronic diarrhea and vomiting&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patients who are taking other types of vasodilators</p>
          </list-item>
        </list>
        <p>Close monitoring of blood pressure and heart rate in the above patients is recommended to avoid severe hypotension and bradycardia. Though methemoglobinemia is a rare complication, patients more susceptible to developing methemoglobinemia require close monitoring for signs and symptoms. The diagnosis of methemoglobinemia requires arterial or venous blood gas with co-oximetry.<xref ref-type="bibr" rid="article-23789.r25">[25]</xref></p>
        <p>The development of tolerance is a significant concern during long-term isosorbide therapy.<xref ref-type="bibr" rid="article-23789.r26">[26]</xref>&#x000a0;Tolerance may develop within as little as 12 to 24 hours,&#x000a0;with a subsequent reduction in the clinical effects of isosorbide; this necessitates the need for a drug-free interval of at least 10 to 12 hours a day. The&#x000a0;recommended&#x000a0; drug-free intervals for preventing the development of tolerance for oral sustained-release isosorbide dinitrate are as follows<xref ref-type="bibr" rid="article-23789.r27">[27]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>12-hour drug-free interval with 40 mg dose</p>
          </list-item>
          <list-item>
            <p>18-hour drug-free interval with 80 mg dose</p>
          </list-item>
          <list-item>
            <p>24-hour drug-free interval with 120 mg dose</p>
          </list-item>
        </list>
        <p>The patients should understand the possibility of developing anginal episodes during the drug-free interval. Chronic isosorbide use without drug-free intervals may cause poor symptom control and endothelial dysfunction due to the release of excessive free radicals.<xref ref-type="bibr" rid="article-23789.r26">[26]</xref></p>
      </sec>
      <sec id="article-23789.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Isosorbide is relatively safe within the therapeutic range. The oral lethal dose LD50 of isosorbide is 2010 mg/kg in rats and 1771 mg/kg in mice. Lethal dose LD50 of isosorbide has not been a topic of sufficient research in the human population. The symptoms of isosorbide overdose may arise from its vasodilating property causing profound systemic hypotension, heart block with bradycardia, syncope, nausea, vomiting, increased intracranial tension (probably along with persistent throbbing headache, fever, confusion), diaphoresis, dizziness, and palpitations. There is limited clinical information available for the management of isosorbide overdose. The venous hypotension and the arterial hypovolemia of isosorbide overdose can be managed clinically by:</p>
        <list list-type="bullet">
          <list-item>
            <p>Administring normal saline. However, this may be hazardous in renal failure and congestive heart failure patients.</p>
          </list-item>
          <list-item>
            <p>Passive elevation of the patient's legs to reduce the venous pooling of blood</p>
          </list-item>
          <list-item>
            <p>Invasive monitoring of central fluid volume is advised in renal failure and congestive heart failure patients.</p>
          </list-item>
          <list-item>
            <p>The usage of epinephrine and other vasoconstrictors is generally not recommended.</p>
          </list-item>
          <list-item>
            <p>The methemoglobinemia associated with isosorbide toxicity is manageable by supportive care and cessation of isosorbide. Methylene blue can work as an antidote.<xref ref-type="bibr" rid="article-23789.r11">[11]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>There is currently no evidence of teratogenicity or carcinogenicity potential of isosorbide.<xref ref-type="bibr" rid="article-23789.r11">[11]</xref></p>
      </sec>
      <sec id="article-23789.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Due to the high prevalence of cardiovascular disease among the general population, effective management of anginal pain and heart failure with significant interprofessional communication plays a crucial role in reducing mortality and readmission rates with long-term benefits of improved exercise tolerance and quality of life. Isosorbide is used to manage anginal pain due to coronary artery disease, and it has approval for use in heart failure. The challenges of isosorbide therapy are drug interactions, adverse effects, and the development of tolerance during chronic isosorbide therapy. Multiple health care professionals such as cardiologists, general practitioners, nurses, pharmacists, home care workers, and dieticians can work together to overcome these challenges of isosorbide therapy. Some of the patient education strategies include educating regarding the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>The possibility of developing orthostatic hypotension in elderly patients</p>
          </list-item>
          <list-item>
            <p>The possibility of developing severe hypotension when combined with Phosphodiesterase(PDE) inhibitors in male patients&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The development of tolerance during chronic isosorbide therapy and drug-free intervals&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The possibility of developing anginal pain during drug-free intervals</p>
          </list-item>
        </list>
        <p>Home care workers can help elderly patients prone to developing orthostatic hypotension with Home safety measures. Nurses and general practitioners should ensure that isosorbide therapy is not an option for patients with erectile dysfunction by taking phosphodiesterase (PDE) inhibitors. Nurses and pharmacists can verify the compliance of the medication, appropriate drug-free intervals, common adverse effects, and drug interactions, and report appropriately to the prescribing general practitioner when needed. Isosorbide therapy in angina and heart failure requires an interprofessional team approach to achieve optimum results.</p>
      </sec>
      <sec id="article-23789.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23789&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23789">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23789/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23789">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23789.s11">
        <title>References</title>
        <ref id="article-23789.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berlin</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Historical aspects of nitrate therapy.</article-title>
            <source>Drugs</source>
            <year>1987</year>
            <volume>33 Suppl 4</volume>
            <fpage>1</fpage>
            <page-range>1-4</page-range>
            <pub-id pub-id-type="pmid">3113909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Ziesche</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>D'Agostino</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferdinand</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sabolinski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Worcel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>JN</given-names>
              </name>
              <collab>African-American Heart Failure Trial Investigators</collab>
            </person-group>
            <article-title>Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.</article-title>
            <source>N Engl J Med</source>
            <year>2004</year>
            <month>Nov</month>
            <day>11</day>
            <volume>351</volume>
            <issue>20</issue>
            <fpage>2049</fpage>
            <page-range>2049-57</page-range>
            <pub-id pub-id-type="pmid">15533851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bortolotti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coccia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brunelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sarti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mazza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bagnato</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barbara</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Isosorbide dinitrate or nifedipine: which is preferable in the medical therapy of achalasia?</article-title>
            <source>Ital J Gastroenterol</source>
            <year>1994</year>
            <season>Oct-Nov</season>
            <volume>26</volume>
            <issue>8</issue>
            <fpage>379</fpage>
            <page-range>379-82</page-range>
            <pub-id pub-id-type="pmid">7703511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gelfond</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rozen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gilat</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation.</article-title>
            <source>Gastroenterology</source>
            <year>1982</year>
            <month>Nov</month>
            <volume>83</volume>
            <issue>5</issue>
            <fpage>963</fpage>
            <page-range>963-9</page-range>
            <pub-id pub-id-type="pmid">6288509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kahrilas</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Management of spastic disorders of the esophagus.</article-title>
            <source>Gastroenterol Clin North Am</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-43</page-range>
            <pub-id pub-id-type="pmid">23452629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mi&#x000f1;ano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Garcia-Tsao</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacology of portal hypertension.</article-title>
            <source>Gastroenterol Clin North Am</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>681</fpage>
            <page-range>681-95</page-range>
            <pub-id pub-id-type="pmid">20951924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daiber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>M&#x000fc;nzel</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Organic Nitrate Therapy, Nitrate Tolerance, and Nitrate-Induced Endothelial Dysfunction: Emphasis on Redox Biology and Oxidative Stress.</article-title>
            <source>Antioxid Redox Signal</source>
            <year>2015</year>
            <month>Oct</month>
            <day>10</day>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>899</fpage>
            <page-range>899-942</page-range>
            <pub-id pub-id-type="pmid">26261901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Etter</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Eto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wardle</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Brautigan</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Activation of myosin light chain phosphatase in intact arterial smooth muscle during nitric oxide-induced relaxation.</article-title>
            <source>J Biol Chem</source>
            <year>2001</year>
            <month>Sep</month>
            <day>14</day>
            <volume>276</volume>
            <issue>37</issue>
            <fpage>34681</fpage>
            <page-range>34681-5</page-range>
            <pub-id pub-id-type="pmid">11461918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lincoln</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Komalavilas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cornwell</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>Pleiotropic regulation of vascular smooth muscle tone by cyclic GMP-dependent protein kinase.</article-title>
            <source>Hypertension</source>
            <year>1994</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>6 Pt 2</issue>
            <fpage>1141</fpage>
            <page-range>1141-7</page-range>
            <pub-id pub-id-type="pmid">8206604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Divakaran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Loscalzo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2017</year>
            <month>Nov</month>
            <day>07</day>
            <volume>70</volume>
            <issue>19</issue>
            <fpage>2393</fpage>
            <page-range>2393-2410</page-range>
            <pub-id pub-id-type="pmid">29096811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tarkin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kaski</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Vasodilator Therapy: Nitrates and Nicorandil.</article-title>
            <source>Cardiovasc Drugs Ther</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>367</fpage>
            <page-range>367-378</page-range>
            <pub-id pub-id-type="pmid">27311574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leier</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Huss</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Magorien</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Unverferth</surname>
                <given-names>DV</given-names>
              </name>
            </person-group>
            <article-title>Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure.</article-title>
            <source>Circulation</source>
            <year>1983</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>817</fpage>
            <page-range>817-22</page-range>
            <pub-id pub-id-type="pmid">6337742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fung</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics of isosorbide dinitrate.</article-title>
            <source>Am Heart J</source>
            <year>1985</year>
            <month>Jul</month>
            <volume>110</volume>
            <issue>1 Pt 2</issue>
            <fpage>213</fpage>
            <page-range>213-6</page-range>
            <pub-id pub-id-type="pmid">4013997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laufen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aumann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leitold</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man.</article-title>
            <source>Arzneimittelforschung</source>
            <year>1983</year>
            <volume>33</volume>
            <issue>7</issue>
            <fpage>980</fpage>
            <page-range>980-4</page-range>
            <pub-id pub-id-type="pmid">6684933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abshagen</surname>
                <given-names>UW</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of isosorbide mononitrate.</article-title>
            <source>Am J Cardiol</source>
            <year>1992</year>
            <month>Nov</month>
            <day>27</day>
            <volume>70</volume>
            <issue>17</issue>
            <fpage>61G</fpage>
            <page-range>61G-66G</page-range>
            <pub-id pub-id-type="pmid">1449102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thadani</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Whitsett</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Relationship of pharmacokinetic and pharmacodynamic properties of the organic nitrates.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1988</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <page-range>32-43</page-range>
            <pub-id pub-id-type="pmid">3135973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sisenwine</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Ruelius</surname>
                <given-names>HW</given-names>
              </name>
            </person-group>
            <article-title>Plasma concentrations and urinary excretion of isosorbide dinitrate and its metabolites in the dog.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>1971</year>
            <month>Feb</month>
            <volume>176</volume>
            <issue>2</issue>
            <fpage>296</fpage>
            <page-range>296-301</page-range>
            <pub-id pub-id-type="pmid">5568780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boden</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Finn</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Thadani</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>Nitrates as an integral part of optimal medical therapy and cardiac rehabilitation for stable angina: review of current concepts and therapeutics.</article-title>
            <source>Clin Cardiol</source>
            <year>2012</year>
            <month>May</month>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>263</fpage>
            <page-range>263-71</page-range>
            <pub-id pub-id-type="pmid">22528319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parker</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>JO</given-names>
              </name>
            </person-group>
            <article-title>Nitrate therapy for stable angina pectoris.</article-title>
            <source>N Engl J Med</source>
            <year>1998</year>
            <month>Feb</month>
            <day>19</day>
            <volume>338</volume>
            <issue>8</issue>
            <fpage>520</fpage>
            <page-range>520-31</page-range>
            <pub-id pub-id-type="pmid">9468470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Echols</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure.</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2006</year>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>423</fpage>
            <page-range>423-31</page-range>
            <pub-id pub-id-type="pmid">17323596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christiansen</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Iversen</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Olesen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Headache characteristics during the development of tolerance to nitrates: pathophysiological implications.</article-title>
            <source>Cephalalgia</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>437</fpage>
            <page-range>437-44</page-range>
            <pub-id pub-id-type="pmid">11037739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thadani</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Side effects of using nitrates to treat angina.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>667</fpage>
            <page-range>667-74</page-range>
            <pub-id pub-id-type="pmid">16907656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inal</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Eg&#x000fc;z</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>The effects of isosorbide dinitrate on methemoglobin reductase enzyme activity and antioxidant states.</article-title>
            <source>Cell Biochem Funct</source>
            <year>2004</year>
            <season>Mar-Apr</season>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-33</page-range>
            <pub-id pub-id-type="pmid">15027102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khaybullina</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zerilli</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.</article-title>
            <source>P T</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>39</volume>
            <issue>11</issue>
            <fpage>749</fpage>
            <page-range>749-58</page-range>
            <pub-id pub-id-type="pmid">25395817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>do Nascimento</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>de Mello</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Methemoglobinemia: from diagnosis to treatment.</article-title>
            <source>Rev Bras Anestesiol</source>
            <year>2008</year>
            <season>Nov-Dec</season>
            <volume>58</volume>
            <issue>6</issue>
            <fpage>651</fpage>
            <page-range>651-64</page-range>
            <pub-id pub-id-type="pmid">19082413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000fc;nzel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Steven</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Daiber</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Organic nitrates: update on mechanisms underlying vasodilation, tolerance and endothelial dysfunction.</article-title>
            <source>Vascul Pharmacol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>105</fpage>
            <page-range>105-13</page-range>
            <pub-id pub-id-type="pmid">25446162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23789.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ko&#x0015b;micki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sadowski</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Szwed</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kowalik</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>What intervals in oral therapy of isosorbide dinitrate in various doses are sufficient to prevent nitrate tolerance?</article-title>
            <source>Med Sci Monit</source>
            <year>2000</year>
            <season>Jul-Aug</season>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>763</fpage>
            <page-range>763-8</page-range>
            <pub-id pub-id-type="pmid">11208406</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
